Skip to main content

Advertisement

SpringerLink
Log in

ST-segment elevation myocardial infarction

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

ST-segment elevation myocardial infarction (MI) is an emergency medical condition. Expediting the steps leading to coronary reperfusion is of critical importance in improving survival after acute MI.

After the diagnosis of acute MI is made, patients should be treated with oxygen, aspirin, nitroglycerin, beta-blockers, heparin, and analgesics, barring any contraindications.

If an experienced cardiac catheterization laboratory is available within 60 to 90 minutes, then catheter-based reperfusion therapy is recommended; otherwise, thrombolysis should be considered as an alternate therapy.

Therapy with a reduced-dose thrombolytic agent and a glycoprotein IIb/IIIa receptor inhibitor appears to be of an added benefit in establishing TIMI (Thrombolysis in Myocardial Infarction) 3 flow, but this approach awaits final approval prior to widespread use.

The adjunctive use of glycoprotein IIb/IIIa receptor inhibitors with percutaneous transluminal coronary angioplasty, with or without stenting, appears to be beneficial and is being used more frequently in the acute setting.

Coronary angiography should be performed in patients who fail to respond to thrombolytic therapy or who have evidence of recurrent ischemia. This procedure should not be routinely performed in patients who have responded to thrombolytic therapy.

Four to 6 days after an acute MI event, assessment of left ventricular function is recommended. Submaximal exercise test (with or without nuclear or echocardiographic imaging) should be considered in patients prior to discharge from the hospital—an exception can be made in patients with one-vessel disease treated successfully with percutaneous transluminal coronary angioplasty. After discharge, a regular exercise test should be obtained 4 to 6 weeks after an uncomplicated acute MI event.

Secondary prevention measures such as weight loss, cessation of smoking, aspirin, beta-blockers, lipid-lowering agents, and angiotensin-converting enzyme inhibitors should be considered in all patients, barring contraindications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Guidry UC, Evans JC, Larson M, et al.: Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999, 100:2054–2059.

    PubMed  CAS  Google Scholar 

  2. Herlitz J, Blohm M, Hartford M, et al.: Delay time in suspected acute myocardial infarction and the importance of its modification. Clin Cardiol 1989, 12:370–374.

    Article  PubMed  CAS  Google Scholar 

  3. Yeghiazarians Y, Braunstein JB, Askari A, et al.: Unstable angina pectoris. N Engl J Med 2000, 342:101–114.

    Article  PubMed  CAS  Google Scholar 

  4. Little WC, Constantinescu M, Applegate RJ, et al.: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-tomoderate coronary artery disease? Circulation 1988, 78:1157–1166.

    PubMed  CAS  Google Scholar 

  5. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000, 36:970–1062.

    Article  PubMed  CAS  Google Scholar 

  6. Goodman SG, Langer A, Ross AM, et al.: Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries- I angiographic substudy. GUSTO-I Angiographic Investigators. Circulation 1998, 97:444–450.

    PubMed  CAS  Google Scholar 

  7. Ridker PM, Antman EM: Pathogenesis and pathology of coronary heart disease syndromes. J Thromb Thrombolysis 1999, 8:167–189.

    Article  PubMed  CAS  Google Scholar 

  8. Muller JE, Abela GS, Nesto RW, et al.: Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994, 23:809–813.

    Article  PubMed  CAS  Google Scholar 

  9. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al.: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994, 90:583–612.

    PubMed  CAS  Google Scholar 

  10. Antman EM, Braunwald E: Acute myocardial infarction. In Heart Disease: A Textbook of Cardiovascular Medicine, edn 6. Edited by Braunwald E, Zipes DP, Libby P. Philadelphia: W B Saunders; 2001:1114–1231. A comprehensive review of the pathophysiology and the therapy of acute MI.

    Google Scholar 

  11. Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). URL: www.acc.org. Accessed October 2001. American College of Cardiology and American Heart Association guidelines for the management of patients with acute MI. These guidelines were updated in 1999 and can be found online at www.acc.org.

  12. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994, 343:311–322. Overview of the results of fibrinolytic therapy from many randomized trials in a large number of patients.

    Google Scholar 

  13. Hochman JS, Sleeper LA, Webb JG, et al.: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999, 341:625–634. The SHOCK trial reported the importance of early revascularization in patients with acute myocardial infarction whose course has been complicated with cardiogenic shock.

    Article  PubMed  CAS  Google Scholar 

  14. Grines CL, Ellis SG, Jones M, et al. : Primary coronary angioplasty versus thrombolytic therapy for acute myocardial infarction (MI):Long-term follow-up of ten randomized trials. Circulation 1999, I-499.

  15. Steinhubl SR, Topol EJ: Stenting in acute myocardial infarction. In In Acute Coronary Syndromes, edn 2. Edited by Topol EJ. New York: Marcel Dekker; 2001:373–390.

    Google Scholar 

  16. Mark DB, Granger CB, Ellis SG, et al.: Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: results from the GUSTO II randomized trial [abstract]. Circulation 1996, 94:168A.

    Google Scholar 

  17. van’t Hof AW, Suryapranata H, de Boer MJ, et al.: Costs of stenting for acute myocardial infarction. Lancet 1998, 351:1817–1822.

    Google Scholar 

  18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349–60. A historically important trial that showed the great benefit of aspirin in individuals with acute MI, both as monotherapy and also in combination with a thrombolytic agent.

    Google Scholar 

  19. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673–82.

    Article  Google Scholar 

  20. Llevadot J, Giugliano RP, Antman EM: Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001, 286:442–449.

    Article  PubMed  CAS  Google Scholar 

  21. The GUSTO III Investigators: A comparison of reteplase and alteplase for acute myocardial infarction. N Engl J Med 1997, 337:1118–1123.

    Article  Google Scholar 

  22. In Time-II Investigators: Intravenous NPA for the treatment of infarcting myocardium early. In TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000, 21:2005–2013.

    Article  Google Scholar 

  23. ASSENT-II Investigators: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999, 354:716–722.

    Article  Google Scholar 

  24. Gurwitz JH, Gore JM, Goldberg RJ, et al.: Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998, 129:597–604.

    PubMed  CAS  Google Scholar 

  25. Mark DB, Hlatky MA, Califf RM, et al.: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995, 332:1418–1424.

    Article  PubMed  CAS  Google Scholar 

  26. Antman EM, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999, 99:2720–2732. A historically important article that addresses the issue of combining a glycoprotein IIb/IIIa inhibitor with thrombolytic therapy as potential therapy in patients with acute MI.

    PubMed  CAS  Google Scholar 

  27. de Lemos JA, Antman EM, Gibson CM, et al.: Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000, 101:239–243.

    PubMed  Google Scholar 

  28. Topol EJ, and the GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001, 357:1905–1914. One of the early clinical trials that addresses the issue of combining lytic therapy with a glycoprotein IIb/IIIa inhibitor as potential therapy in patients with acute MI.

    Article  PubMed  CAS  Google Scholar 

  29. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605-613.

  30. Montalescot G, Barragan P, Wittenberg O, et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344:1895–1903.

    Article  PubMed  CAS  Google Scholar 

  31. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.

    Article  PubMed  CAS  Google Scholar 

  32. Ross AM, Molhoek P, Lundergan C, et al.: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001, 104:648–652.

    PubMed  CAS  Google Scholar 

  33. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94:911–21.

    PubMed  CAS  Google Scholar 

  34. The GUSTO IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775–782.

    Article  Google Scholar 

  35. Hennekens CH, Chae CU: Beta-blockers. In In Clinical Trials in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Edited by Hennekens CH. Philadelphia: W B Saunders, 1999:76–94.

    Google Scholar 

  36. Yusuf S, Collins R, MacMahon S, et al.: Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988, 1:1088–1092.

    Article  PubMed  CAS  Google Scholar 

  37. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994, 343:1115–1122.

  38. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345:669–685.

  39. Latini R, Maggioni AP, Flather M, et al.: ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995, 92:3132–3137.

    PubMed  CAS  Google Scholar 

  40. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J of Med 1988, 319:385–392.

    Article  Google Scholar 

  41. The Danish Study Group on Verapamil in Myocardial Infarction: Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990, 66:33I–40I.

  42. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.

    Article  PubMed  CAS  Google Scholar 

  43. Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389. A historically significant study that demonstrates the great importance of lipid-lowering therapy with a statin as a secondary prevention measure in patients with coronary artery disease.

    Article  Google Scholar 

  44. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  45. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

    Article  Google Scholar 

  46. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–97. The most recent Expert Panel recommendations of the National Cholesterol Education Program.

  47. Antman EM: Magnesium in acute myocardial infarction: overview of available evidence. Am Heart J 1996, 132:487–495;496–502.

    Article  PubMed  CAS  Google Scholar 

  48. ISIS-4 Collaborative Group: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345:669–685.

    Article  Google Scholar 

  49. Becker RC, Corrao JM, Bovill EG, et al.: Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990, 119:1254–1261.

    Article  PubMed  CAS  Google Scholar 

  50. Bassenge E, Fink N, Skatchkov M, et al.: Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998, 102:67–71.

    Article  PubMed  CAS  Google Scholar 

  51. Boyko WL, Glick HA, Schulman KA: ACE inhibitors in the management of congestive heart failure: comparative economic data. Am Heart J 1999, 137:S115–119.

    Article  PubMed  Google Scholar 

  52. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  53. Kessler JM: Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective. Am Heart J 1999, 137:S111–114.

    Article  PubMed  CAS  Google Scholar 

  54. Jackson JD: Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies—an industry perspective. Am Heart J 1999, 137:S105–110.

    Article  PubMed  CAS  Google Scholar 

  55. Ectht DS, Leibson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.

    Article  Google Scholar 

  56. The CAST Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227–233.

    Article  Google Scholar 

  57. Mueller HS: Role of intra-aortic counterpulsation in cardiogenic shock and acute myocardial infarction. Cardiology 1994, 84:168–174.

    PubMed  CAS  Google Scholar 

  58. Stone GW, Marsalese D, Brodie BR, et al.: A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol 1997, 29:1459–1467.

    Article  PubMed  CAS  Google Scholar 

  59. Chen JM, DeRose JJ, Slater JP, et al.: Improved survival rates support left ventricular assist device implantation early after myocardial infarction. J Am Coll Cardiol 1999, 33:1903–1908.

    Article  PubMed  CAS  Google Scholar 

  60. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605–613. A historically important publication assessing the role of hormone replacement therapy in postmenopausal women as means of secondary prevention.

    Article  PubMed  CAS  Google Scholar 

  61. Killip T 3rd, Kimball JT: Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967, 20:457–464.

    Article  PubMed  Google Scholar 

  62. Morrow DA, Antman EM, Charlesworth A, et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000, 102:2031–2037.

    PubMed  CAS  Google Scholar 

  63. Volpi A, De VC, Franzosi MG, et al.: Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. The Ad Hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-2 Data Base. Circulation 1993, 88:416–429.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street, 02115, Boston, MA, USA

    Yerem Yeghiazarians MD & Peter H. Stone MD

Authors
  1. Yerem Yeghiazarians MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter H. Stone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeghiazarians, Y., Stone, P.H. ST-segment elevation myocardial infarction. Curr Treat Options Cardio Med 4, 3–23 (2002). https://doi.org/10.1007/s11936-002-0023-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-002-0023-3

Keywords

Search

Navigation